Hereditary spherocytosis natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
Line 125: Line 125:
}}</ref>
}}</ref>
* Patients with hereditary spherocytosis may remain undiagnosed for years if their hemolysis is mild.
* Patients with hereditary spherocytosis may remain undiagnosed for years if their hemolysis is mild.
* Overall, the long-term outlook for people with [[hereditary spherocytosis]] (HS) is usually good with treatment. However, it may depend on the severity of the condition in each person.  
* Overall, the long-term outlook for people with [[hereditary spherocytosis]] (HS) is usually good with treatment. However, it may depend on the severity of the condition in each person.  
* People with very mild [[Hereditary spherocytosis|HS]] may not have any signs or symptoms unless an environmental "trigger" causes symptom onset. In many cases, no specific therapy is needed other than monitoring for  and watching for signs and symptoms. Moderately and severely affected people are likely to benefit from splenectomy.<ref name="pmid220550202">{{cite journal| author=Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ, General Haematology Task Force of the British Committee for Standards in Haematology| title=Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update. | journal=Br J Haematol | year= 2012 | volume= 156 | issue= 1 | pages= 37-49 | pmid=22055020 | doi=10.1111/j.1365-2141.2011.08921.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22055020  }}</ref>  
* People with very mild [[Hereditary spherocytosis|HS]] may not have any signs or symptoms unless an environmental "trigger" causes symptom onset. In many cases, no specific therapy is needed other than monitoring for  and watching for signs and symptoms. Moderately and severely affected people are likely to benefit from splenectomy.<ref name="pmid220550202">{{cite journal| author=Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ, General Haematology Task Force of the British Committee for Standards in Haematology| title=Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update. | journal=Br J Haematol | year= 2012 | volume= 156 | issue= 1 | pages= 37-49 | pmid=22055020 | doi=10.1111/j.1365-2141.2011.08921.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22055020  }}</ref>  
* Most people who undergo [[splenectomy]] are able to maintain a normal [[hemoglobin]] level. However, people with severe [[Hereditary spherocytosis|HS]] may remain anemic post-splenectomy, and may need [[blood transfusions]] during an infection.
* Most people who undergo [[splenectomy]] are able to maintain a normal [[hemoglobin]] level. However, people with severe [[Hereditary spherocytosis|HS]] may remain anemic post-splenectomy, and may need [[blood transfusions]] during an infection.
 
* In all people who undergo [[splenectomy]], there is a lifelong, increased risk of developing a life-threatening infection [[Sepsis|(sepsis)]]. Although most septic episodes have been observed in children whose spleens were removed in the first years of life, older children and adults also are susceptible. Fortunately, taking certain precautions can reduce this risk and can prevent minor infections from becoming life-threatening
* Information about life expectancy in the medical literature appears to be limited. However, we are not aware of reports that state that life expectancy is known to be significantly shortened in people without other medical problems who are managed appropriately. In all people who undergo [[splenectomy]], there is a lifelong, increased risk of developing a life-threatening infection [[Sepsis|(sepsis)]]. Although most septic episodes have been observed in children whose spleens were removed in the first years of life, older children and adults also are susceptible. Fortunately, taking certain precautions can reduce this risk and can prevent minor infections from becoming life-threatening


==References==
==References==

Revision as of 17:40, 2 December 2018

Hereditary spherocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hereditary spherocytosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hereditary spherocytosis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hereditary spherocytosis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hereditary spherocytosis natural history, complications and prognosis

CDC on Hereditary spherocytosis natural history, complications and prognosis

Hereditary spherocytosis natural history, complications and prognosis in the news

Blogs on Hereditary spherocytosis natural history, complications and prognosis

Directions to Hospitals Treating Hereditary spherocytosis

Risk calculators and risk factors for Hereditary spherocytosis natural history, complications and prognosis

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Natural History

  • The clinical course of hereditary spherocytosis is variable depending upon the severity of disease.[1]
  • During infancy, hemoglobin level falls rapidly after 20 days of birth leading to transient & severe anemia, causing inappropriate erythrocyte response and splenic filtering function.[2]
  • About 20-30% of patients have mild disease with compensated hemolysis.
  • About 60-70% of patients have moderate disease, presenting in childhood but can present at any age.
  • About 3-5% of patients have severe hereditary disease with life threatening anemia, requiring regular transfusions to maintain a hemoglobin concentration of greater than 60g/L.
  • Without regular transfusions or splenectomy or both, patients may develop kernicterus, severe hemolytic anemia, gallstones, growth retardation, delayed sexual maturation, extramedullary hematopoiesis with hepatosplenomegaly and bony changes (thalassemic facies).[3]


  • Hereditary apherocytosis can present at any age and with any severity, with case reports describing a range of presentations, from hydrops fetalis in utero through diagnosis in the ninth decade of life. [4][5][6]

Hemolytic anemia — A classification for HS has been developed based on the severity of anemia and markers of hemolysis (reticulocyte count and bilirubin) [7][8]; it characterizes patients as having one of the following:

●HS trait – Normal hemoglobin and reticulocyte count

●Mild HS (20 to 30 percent of cases) – Hemoglobin 11 to 15 g/dL; reticulocytes 3 to 6 percent; bilirubin 17 to 34 micromol/L

●Moderate HS (60 to 75 percent of cases) – Hemoglobin 8 to 12 g/dL; reticulocytes >6 percent; bilirubin >34 micromol/L

●Severe HS (5 percent of cases) – Hemoglobin 6 to 8 g/dL; reticulocytes >10 percent; bilirubin >51 micromol/L

  • Neonates may have a relatively normal hemoglobin level at birth that is followed by development of severe anemia, especially during the first three weeks and, in some cases, the first year of life, when the erythropoietic response may not be adequate.
  • According to one review, more than half of neonates with HS are not anemic during the first week of life [9].
  • However, anemia can develop after several days, and is most likely to be severe during the second or third week of life. Some infants require chronic transfusions during the first year; however, transfusion dependence beyond the first year of life is unusual.
  • In some cases, co-inheritance of another disorder affecting RBC survival such as sickle cell disease or thalassemia can influence the severity of anemia and make diagnosis more challenging. [10]

Complications

  • The complications of hereditary spherocytosis include:[11][12][13]
    • hemolytic anemia
    • jaundice
    • kernicterus
    • cholelithiasis
    • hemolytic, aplastic and megaloblastic crises
    • growth failure
    • leg ulcers
    • skeletal abnormalities resulting from bone marrow expansion
    • multiple myeloma
    • leukemia


Exacerbations of anemia in certain settings:

Infections that impair RBC production in the bone marrow and thus diminish the capacity to compensate for chronic hemolysis may lead to a period of aplasia. A commonly cited cause of transient aplastic crisis is parvovirus B19 infection; other viral or bacterial infections may also cause transient aplasia. This is because individuals with chronic hemolysis are highly dependent on the accelerated production of new RBCs by the bone marrow, and they can experience a rapid drop in hemoglobin level when the bone marrow is unable to compensate for hemolysis. If an individual with HS develops a precipitous decline in hemoglobin level or reticulocyte count, testing for parvovirus infection is appropriate.

●Conditions that increase the size of the spleen, such as infectious mononucleosis, may cause increased splenic pooling of RBCs and/or increased hemolysis.

●Individuals who develop folate, vitamin B12, or iron deficiency may be unable to produce sufficient RBCs to compensate for those lost by hemolysis.

Anemia may worsen during pregnancy, as the RBC mass and plasma volume expand to meet the physiologic needs of the pregnancy. Attention to folic acid supplantation and iron stores are also important so as not to impair RBC production.

●Individuals who experience a decline from their baseline hemoglobin level and/or reduction in baseline reticulocyte count are likely to require more frequent monitoring and/or additional testing, details of which will depend on the associated symptoms and laboratory findings.

Complications of hemolysis — Common complications of hemolysis include neonatal jaundice, splenomegaly, and pigment gallstones.

●Rarely, hemolysis may be severe enough to cause extramedullary hematopoiesis and/or growth delay.[14][15] A small subset of these children may be at risk for iron overload due to increased iron absorption and/or transfusions, although the majority of patients with HS do not develop iron overload.

●Other rare complications that have been reported include leg ulcers, priapism, neuromuscular disorders, cardiac disease, and gout; in some cases, these may represent coincidental rather than causal associations.[16]

Neonatal jaundice — HS may present in the neonatal period with jaundice and hyperbilirubinemia, and the serum bilirubin level may not peak until several days after birth. Some experts have proposed that HS is underdiagnosed as a cause of neonatal jaundice.[17] A requirement for phototherapy and/or exchange transfusion during this period is common.

Hyperbilirubinemia may be exacerbated by concomitant Gilbert syndrome.

Splenomegaly — Splenomegaly is rare in neonates, but can often be seen in older children and adults with HS. Early reports of family studies found palpable spleens in over three-fourths of affected members, but this may reflect a skewed population with the most severe disease. In these studies, the relationship between disease severity and splenic size was not linear.[18]

●There is no evidence of an increased risk of splenic rupture.

Pigment gallstones — Pigment (bilirubin) gallstones are common in individuals with HS and may be the presenting finding in adults. Gallstones are unlikely before the age of 10 years but are seen in as many as half of adults, especially those with more severe hemolysis. Gallstones appear to be more common in individuals with Gilbert syndrome.[19]

Obstructive jaundice or cholecystitis is treated similarly to that in individuals without HS. If cholecystectomy is performed, it may be worthwhile to discuss whether splenectomy was also planned, as the procedures could be combined; however, splenectomy should not be routinely performed during cholecystectomy.[20]

Prognosis

  • The prognosis of patients with hereditary spherocytosis is usually good with early diagnosis, regular followup and management.[21]
  • Patients with hereditary spherocytosis may remain undiagnosed for years if their hemolysis is mild.
  • Overall, the long-term outlook for people with hereditary spherocytosis (HS) is usually good with treatment. However, it may depend on the severity of the condition in each person.
  • People with very mild HS may not have any signs or symptoms unless an environmental "trigger" causes symptom onset. In many cases, no specific therapy is needed other than monitoring for  and watching for signs and symptoms. Moderately and severely affected people are likely to benefit from splenectomy.[22]
  • Most people who undergo splenectomy are able to maintain a normal hemoglobin level. However, people with severe HS may remain anemic post-splenectomy, and may need blood transfusions during an infection.
  • In all people who undergo splenectomy, there is a lifelong, increased risk of developing a life-threatening infection (sepsis). Although most septic episodes have been observed in children whose spleens were removed in the first years of life, older children and adults also are susceptible. Fortunately, taking certain precautions can reduce this risk and can prevent minor infections from becoming life-threatening

References

  1. Olga Ciepiela (2018). "Old and new insights into the diagnosis of hereditary spherocytosis". Annals of translational medicine. 6 (17): 339. doi:10.21037/atm.2018.07.35. PMID 30306078. Unknown parameter |month= ignored (help)
  2. F. Delhommeau, T. Cynober, P. O. Schischmanoff, P. Rohrlich, J. Delaunay, N. Mohandas & G. Tchernia (2000). "Natural history of hereditary spherocytosis during the first year of life". Blood. 95 (2): 393–397. PMID 10627440. Unknown parameter |month= ignored (help)
  3. Perrotta, Silverio; Gallagher, Patrick G; Mohandas, Narla (2008). "Hereditary spherocytosis". The Lancet. 372 (9647): 1411–1426. doi:10.1016/S0140-6736(08)61588-3. ISSN 0140-6736.
  4. Perrotta S, Gallagher PG, Mohandas N (2008). "Hereditary spherocytosis". Lancet. 372 (9647): 1411–26. doi:10.1016/S0140-6736(08)61588-3. PMID 18940465.
  5. Whitfield CF, Follweiler JB, Lopresti-Morrow L, Miller BA (1991). "Deficiency of alpha-spectrin synthesis in burst-forming units-erythroid in lethal hereditary spherocytosis". Blood. 78 (11): 3043–51. PMID 1954389.
  6. Eber SW, Armbrust R, Schröter W (1990). "Variable clinical severity of hereditary spherocytosis: relation to erythrocytic spectrin concentration, osmotic fragility, and autohemolysis". J Pediatr. 117 (3): 409–16. PMID 2391596.
  7. Bolton-Maggs PH, Stevens RF, Dodd NJ, Lamont G, Tittensor P, King MJ; et al. (2004). "Guidelines for the diagnosis and management of hereditary spherocytosis". Br J Haematol. 126 (4): 455–74. doi:10.1111/j.1365-2141.2004.05052.x. PMID 15287938.
  8. Bolton-Maggs PH, Stevens RF, Dodd NJ, Lamont G, Tittensor P, King MJ; et al. (2004). "Guidelines for the diagnosis and management of hereditary spherocytosis". Br J Haematol. 126 (4): 455–74. doi:10.1111/j.1365-2141.2004.05052.x. PMID 15287938.
  9. Christensen RD, Yaish HM, Gallagher PG (2015). "A pediatrician's practical guide to diagnosing and treating hereditary spherocytosis in neonates". Pediatrics. 135 (6): 1107–14. doi:10.1542/peds.2014-3516. PMC 4444801. PMID 26009624.
  10. Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ, General Haematology Task Force of the British Committee for Standards in Haematology (2012). "Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update". Br J Haematol. 156 (1): 37–49. doi:10.1111/j.1365-2141.2011.08921.x. PMID 22055020.
  11. Sayeeda Huq, Mark A. C. Pietroni, Hafizur Rahman & Mohammad Tariqul Alam (2010). "Hereditary spherocytosis". Journal of health, population, and nutrition. 28 (1): 107–109. PMID 20214092. Unknown parameter |month= ignored (help)
  12. Friedman, Ellen Wolkin; Williams, Jeannine C.; van Hook, Lucille (1988). "Hereditary spherocytosis in the elderly". The American Journal of Medicine. 84 (3): 513–516. doi:10.1016/0002-9343(88)90275-6. ISSN 0002-9343.
  13. Guitton, C.; Garçon, L.; Cynober, T.; Gauthier, F.; Tchernia, G.; Delaunay, J.; Leblanc, T.; Thuret, I.; Bader-Meunier, B. (2008). "Sphérocytose héréditaire : recommandations pour le diagnostic et la prise en charge chez l'enfant". Archives de Pédiatrie. 15 (9): 1464–1473. doi:10.1016/j.arcped.2008.04.023. ISSN 0929-693X.
  14. Bastion Y, Coiffier B, Felman P, Assouline D, Tigaud JD, Espinouse D; et al. (1990). "Massive mediastinal extramedullary hematopoiesis in hereditary spherocytosis: a case report". Am J Hematol. 35 (4): 263–5. PMID 2239921.
  15. Smith J, Rahilly M, Davidson K (2011). "Extramedullary haematopoiesis secondary to hereditary spherocytosis". Br J Haematol. 154 (5): 543. doi:10.1111/j.1365-2141.2011.08692.x. PMID 21517821.
  16. Perrotta S, Gallagher PG, Mohandas N (2008). "Hereditary spherocytosis". Lancet. 372 (9647): 1411–26. doi:10.1016/S0140-6736(08)61588-3. PMID 18940465.
  17. Christensen RD, Henry E (2010). "Hereditary spherocytosis in neonates with hyperbilirubinemia". Pediatrics. 125 (1): 120–5. doi:10.1542/peds.2009-0864. PMID 19948573.
  18. MACKINNEY AA (1965). "HEREDITARY SPHEROCYTOSIS; CLINICAL FAMILY STUDIES". Arch Intern Med. 116: 257–65. PMID 14315658.
  19. del Giudice EM, Perrotta S, Nobili B, Specchia C, d'Urzo G, Iolascon A (1999). "Coinheritance of Gilbert syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis". Blood. 94 (7): 2259–62. PMID 10498597.
  20. Ruparel RK, Bogert JN, Moir CR, Ishitani MB, Khan SP, Rodriguez V; et al. (2014). "Synchronous splenectomy during cholecystectomy for hereditary spherocytosis: is it really necessary?". J Pediatr Surg. 49 (3): 433–5. doi:10.1016/j.jpedsurg.2013.05.012. PMID 24650472.
  21. Yuki Tateno, Ryoji Suzuki & Yukihiro Kitamura (2016). "Previously undiagnosed hereditary spherocytosis in a patient with jaundice and pyelonephritis: a case report". Journal of medical case reports. 10 (1): 337. doi:10.1186/s13256-016-1144-8. PMID 27906107. Unknown parameter |month= ignored (help)
  22. Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ, General Haematology Task Force of the British Committee for Standards in Haematology (2012). "Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update". Br J Haematol. 156 (1): 37–49. doi:10.1111/j.1365-2141.2011.08921.x. PMID 22055020.

Template:WH Template:WS